OverviewChartProfileKey statisticsFinancialsNews
Derivatives
TraderScreen

GALAPAGOS N.V./  BE0003818359  /

Stuttgart
2024-11-15  8:09:15 AM Chg. -0.140 Volume Bid10:00:01 PM Ask10:00:01 PM Market Capitalization Dividend Y. P/E Ratio
26.300EUR -0.53% 0
Turnover: 0.000		 -Bid Size: - -Ask Size: - 1.68 bill.EUR - 7.96
Newsfile Corp 10-25 Trundless Expands Focus on Ecuador as a Top 2024 Travel Spot for Nature and Culture
Newsfile Corp 09-06 Metropolitan Touring Achieves Sustainability Benchmark with Carbon-Neutral Commitment
GlobeNewswire 08-27 Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy
GlobeNewswire 08-27 Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy
GlobeNewswire 08-23 Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, G...
GlobeNewswire 08-22 Inspirato Introduces “Inspirato Invited”
GlobeNewswire 08-20 Galapagos receives transparency notification from FMR LLC
GlobeNewswire 08-01 Galapagos reports half-year 2024 financial results and provides second quarter business update
GlobeNewswire 06-14 Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at...
GlobeNewswire 05-30 Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively licens...
GlobeNewswire 05-16 Galapagos creates new subscription right plans
GlobeNewswire 05-15 Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ dec...
GlobeNewswire 05-02 Galapagos reports first quarter 2024 financial results  
GlobeNewswire 04-30 Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and E...
GlobeNewswire 04-04 Galapagos showcases innovative approach in hematological cancer care with clinical and translational...
GlobeNewswire 03-28 Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
GlobeNewswire 03-26 Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
GlobeNewswire 02-22 Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Cl...
GlobeNewswire 02-22 Galapagos announces full year 2023 results and outlook for 2024
GlobeNewswire 02-15 Galapagos presents at EBMT-EHA annual meeting 2024
GlobeNewswire 02-05 NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer
GlobeNewswire 01-31 Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
GlobeNewswire 01-04 Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further exp...
GlobeNewswire 01-03 Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule dru...
GlobeNewswire 01-02 Galapagos signs agreement to transfer Jyseleca® business to Alfasigma